3 Days Versus 5 Days Amoxicillin for Chest-indrawing Childhood Pneumonia in Malawi

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

3000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial evaluates the duration of treatment of chest-indrawing pneumonia in children. Half the children will receive 3 days of amoxicillin dispersible tablets (DT) and then 2 days of placebo, while the other half will receive 5 days of amoxicillin DT.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

3 Days Amoxicillin Versus Placebo for Fast Breathing Childhood Pneumonia in Malawi

NCT02760420

Pneumonia

COMPLETED PHASE4

Short-course Antimicrobial Therapy for Paediatric Respiratory Infections

NCT02380352

Community-acquired Pneumonia

COMPLETED PHASE4

Cotrimoxazole Versus Amoxicillin in the Treatment of Community Acquired Pneumonia in Children Aged 2-59 Months

NCT00933049

Childhood Pneumonia

COMPLETED PHASE3

Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia

NCT02258763

Pneumonia

COMPLETED PHASE4

Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.

NCT03031210

Community-acquired Pneumonia

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3 days amoxicillin + 2 days placebo

3 days amoxicillin DT + 2 days placebo DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).

Group Type EXPERIMENTAL

Amoxicillin

Intervention Type DRUG

Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Placebo

Intervention Type DRUG

Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

5 days amoxicillin

5 days amoxicillin DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).

Group Type ACTIVE_COMPARATOR

Amoxicillin

Intervention Type DRUG

Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amoxicillin

Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Intervention Type DRUG

Placebo

Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, 2 to 59 months of age.
* History of cough \<14 days or difficult breathing with chest-indrawing.
* Ability and willingness of child's caregiver to provide informed consent and to be available for follow-up for the planned duration of the study, including accepting a home visit if he/she fails to return to Kamuzu Central Hospital (KCH) for a scheduled study follow-up visit.

Exclusion Criteria

* If chest-indrawing observed at screening resolves after bronchodilator challenge, among those with wheeze at screening.
* Severe respiratory distress (e.g., grunting, nasal flaring, head nodding, or severe chest-indrawing).
* Presence of World Health Organization (WHO) Integrated Management of Childhood Illness (IMCI) danger signs including: lethargy or unconsciousness, convulsions, vomiting everything, or inability to drink or breastfeed.
* Hypoxia (SaO2 \< 90% on room air, as assessed by a Lifebox pulse oximeter).
* Stridor when calm.
* HIV-1 seropositivity or HIV-1 exposure, assessed as follows:

* An HIV-positive result upon rapid antibody test will exclude any child from this study.
* If a child is less than 12 months or age with a positive rapid test result, the child will be referred to receive additional confirmatory HIV testing (e.g., dried blood spot filter paper test) and follow-up from KCH staff, as per standard of care. Even if the confirmatory HIV testing subsequently shows that child is HIV-negative, he or she will remain excluded from the study.
* If a child is less than 24 months of age and has an HIV-negative result upon rapid antibody test, the child's biological mother's HIV status will need to be assessed. If the mother is HIV-positive, the child will be excluded. If the mother has a documented HIV-negative test result from within the past 6 weeks, the child will be included. If the mother does not have documentation of an HIV-negative test result, she will be tested via rapid antibody testing to determine the child's eligibility for this study.
* If a child is over 24 months of age, an HIV-negative rapid antibody test is required for inclusion in the study.
* Note: If a child has documentation of an HIV-negative test result from within the past 6 weeks, that test result will be used for the child's eligibility assessment according to the algorithm described above.
* Severe acute malnutrition (i.e., weight for height/length \< -3 SD, mid-upper arm circumference \<115 mm, or edema).
* Possible tuberculosis (coughing for more than 14 days).
* Severe anemia, classified by WHO pocketbook guidelines (i.e., severe palmar pallor or hemoglobin \<8.0 g/dL)
* Severe malaria, classified by WHO pocketbook guidelines (e.g., positive malaria rapid diagnostic test (mRDT) with any danger sign, stiff neck, abnormal bleeding, clinical jaundice, or hemoglobinuria)
* Known allergy to penicillin or amoxicillin.
* Receipt of an antibiotic treatment in the 48 hours prior to the study based on caregiver's self-report and/or documentation in child's medical record.
* Hospitalized within 14 days prior to the study.
* Living outside Lilongwe urban area, the study catchment area.
* Any medical or psychosocial condition or circumstance that, in the opinion of the investigators, would interfere with the conduct of the study or for which study participation might jeopardize the child's health.
* Any non-pneumonia acute medical illness which requires antibiotic treatment per local standard of care.
* Participation in a clinical study of another investigational product within 12 weeks prior to randomization or planning to begin participation during this study.
* Prior participation in an Innovative Treatments in Pneumonia (ITIP) study during a previous pneumonia diagnosis.

Minimum Eligible Age

2 Months

Maximum Eligible Age

59 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No